BioNTech SE (BNTX) BNT113 Combo Misses PFS; Trial Continues to Evaluate OS

The FDA launched a Rare Disease Framework Initiative to boost drug development for rare diseases. Arrowhead Pharmaceuticals reported a 73% decrease in tau protein in a Phase 1/2a study of ARO-MAPT. First Tracks Biotherapeutics announced positive Phase 1b results for ANB033 in celiac disease. BioNTech's BNT113 missed its first primary endpoint in a head and neck cancer trial. GSK plans to cut over 1,000 jobs at a Belgium site.

FDA launches Rare Disease Framework Initiative to gather public input on drug development for rare conditions. BioNTech's BNT113 failed to meet progression-free survival goal in a Phase II/III trial. Viking Therapeutics begins Phase III trials for oral obesity drug VK2735, following promising Phase II results.

BioNTech's mRNA cancer vaccine BNT113, combined with pembrolizumab, missed its primary endpoint of progression-free survival in a Phase 2/3 trial for HPV16-positive head and neck cancer. The trial will continue to assess overall survival, which, if positive, could still validate the treatment. BioNTech is also developing other mRNA-based cancer therapies, including BNT111 and BNT116, with mixed results so far.

Moderna and MSD announced successful Phase III trial results for a personalized mRNA cancer vaccine, showing reduced melanoma recurrence. Roche and BioNTech halted a Phase II trial for colorectal cancer. Moderna's shares surged 60%, MSD's rose 6%. Analysts discuss implications for Swiss pharma giants Roche and Novartis, focusing on trial differences and market potential. Challenges include manufacturing time and cost.

BioNTech's BNT113 mRNA therapy failed to improve progression-free survival in a trial for HPV16-linked head and neck cancer. The study continues to test BNT113 with Keytruda for overall survival. BioNTech shares fell 6.1% premarket. The company faces competition from Moderna and Merck's recent melanoma trial success.

BioNTech (BNTX) shares dropped 7% after its mRNA cancer immunotherapy BNT113 failed to show a statistically significant progression-free survival benefit in a late-stage trial. Analysts noted broader challenges for mRNA cancer vaccines, while the company continues to assess overall survival data. Analysts' price targets range from $105 to $130.